UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17
UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Buy rating and announces Price Target of $17.
Stocks · News reference
Shattuck Labs Plans To Evaluate SL-325 In Phase 2 Clinical Trial In Patients With Moderate To Severe Hidradenitis Suppurativa
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14
Wedbush analyst David Nierengarten maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and raises the price target from $11 to $14.
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Needham analyst Joseph Stringer maintains Shattuck Labs (NASDAQ:STTK) with a Buy and raises the price target from $17 to $19.